Table 2 Demographic and baseline clinical characteristics of participants who took all the three doses of Eurartesim® and completed study procedures
Main study | Nested cohort | Total n (%) | |
|---|---|---|---|
Variable | N = 9,589 | 1,002 | 10,591 |
Country (n (%)) | |||
Burkina Faso | 2,718 (28. 3) | 299 (29. 8) | 3,017 (28. 5) |
Ghana | 4,119 (43. 0) | 444 (44. 3) | 4,563 (43. 1) |
Mozambique | 1,876 (19. 6) | 89 (8. 9) | 1,965 (18. 6) |
Tanzania | 876 (9. 1) | 170 (17. 0) | 1,046 (9. 9) |
Gender (n (%)) | |||
Female | 5,068 (52. 8) | 519 (51. 8) | 5,587 (52. 7) |
Male | 4,521 (47. 2) | 483 (48. 2) | 5,004 (47. 3) |
Age group (n (%)) | |||
<6 | 4,654 (48. 5) | 331 (33. 0) | 4,985 (47. 1) |
6 - <13 | 2,612 (27. 2) | 398 (37. 7) | 3,010 (28. 4) |
13- <18 | 753 (7. 8) | 112 (11. 2) | 865 (8. 2) |
>18 | 1,570 (16. 4) | 161 (16. 1) | 1,731 (16. 3) |
Plasmodium positivity (n (%)) | |||
RDT only | 3,170 (33. 0) | - | 3,170(29. 9) |
Microscopy only | 1,405 (14. 6) | 274 (27. 4) | 1,679 (15. 9) |
Both RDT and microscopy | 4,984 (52. 0) | 728 (72. 6) | 5,712(53. 9) |
Presumptive diagnosis | 30 (0. 3) | - | 30 (0. 3) |
*Parasite density (/μL) ( P. falciparum) * (n (%)) | |||
No parasite observed | 37 (0. 6) | 8 (0. 8) | 45 (0. 6) |
<50 | 421 (6. 6) | 80 (8. 0) | 501 (6. 8) |
50- < 500 | 1,282 (20. 1) | 214 (21. 5) | 1,496 (20. 3) |
500- < 5,000 | 1,800 (28. 3) | 265 (26. 6) | 2,065 (28. 0) |
5000- < 50,000 | 1,477 (23. 2) | 268 (26. 9) | 1,745 (23. 7) |
≥50,000 | 1,354 (21. 2) | 160 (16. 1) | 1,514 (20. 6) |